Susceptibility of Urinary Tract Bacteria to Newer Antimicrobial Drugs by Mehta, Manjula et al.
 
OA Maced J Med Sci electronic publication ahead of print,  
published on January 25, 2016 as http://dx.doi.org/10.3889/oamjms.2016.020 
_______________________________________________________________________________________________________________________________ 
OA Maced J Med Sci.                                                                                                                                                                                                                          1 
 
ID Design 2012/DOOEL Skopje 
Open Access Macedonian Journal of Medical Sciences. 
http://dx.doi.org/10.3889/oamjms.2016.020 
eISSN: 1857-9655 
Basic Science 
  
 
 
 
Susceptibility of Urinary Tract Bacteria to Newer Antimicrobial 
Drugs 
 
 
Manjula Mehta
*
, Jyoti Sharma, Sonia Bhardwaj 
 
Dr. Harvansh Singh Judge Institute of Dental Science & Hospital, Panjab University, Chandigarh, India 
 
 
 
Citation: Mehta M, Sharma J, Bhardwaj S. Susceptibility 
of Urinary Tract Bacteria to Newer Antimicrobial Drugs. 
OA Maced J Med Sci. 
http://dx.doi.org/10.3889/oamjms.2016.020 
Key words: Antibiotic; Urinary tract infection; 
uropathogens. 
*
Correspondence: Manjula Mehta. Dr. Harvansh Singh 
Judge Institute of Dental Science & Hospital, Panjab 
University, Chandigarh, India. E-mail: 
udeshmehta@rediffmail.com 
Received: 17-Sep-2014; Revised: 17-Dec-2014; 
Accepted: 02-Jan-2015; Online first: 25-Jan-2016 
Copyright: © 2016 Manjula Mehta, Jyoti Sharma, Sonia 
Bhardwaj. This is an open access article distributed under 
the terms of the Creative Commons Attribution License, 
which permits unrestricted use, distribution, and 
reproduction in any medium, provided the original author 
and source are credited. 
Competing Interests: The authors have declared that no 
competing interests exist. 
 
 
 
 
 
Abstract  
Urinary tract infections (UTIs) are among the commonest types of bacterial infections. The antibiotic 
treatment for UTIs is associated with important medical and economic implications. Many different 
microorganisms can cause UTIs though the most common pathogens are E. coli and members of 
family Enterobacteriaceae. The knowledge of etiology and antibiotic resistance pattern of the 
organisms causing urinary tract infection is essential. The present study was undertaken to 
evaluate trends of antibiotic susceptibility of commonly isolated uropathogens using newer 
antimicrobial agents, prulifloxacin, fosfomycin (FOM) and doripenem. We conclude that maintaining 
a record of culture results and the antibiogram may help clinicians to determine the empirical and/or 
specific treatment based on the antibiogram of the isolate for better therapeutic outcome. 
 
 
 
 
 
 
 
Introduction 
 
Urinary tract infection (UTI) has long been 
recognized as one of the commonest bacterial 
infection [1] which is prevalent in both community and 
health care settings. Symptomatic infections are 
common and are associated with morbidity and rarely 
mortality. However asymptomatic infections are more 
common. Any demarcation regarding its prevalence in 
specific age group is not been reported. It may infect 
individuals from different age groups and from both 
the sexes [2]. It occurs as both complicated and 
uncomplicated infection, uncomplicated one is 
common in healthy adults and non-pregnant females 
whereas complicated UTI is frequently associated with 
structural and functional abnormalities [3].
 
Though the 
sufficient treatment options facilitate the management 
of the disease but increasing resistance towards 
various antimicrobial agents leads to numerous 
problems. Multi-drug resistant (MDR) uro-pathogens 
have leaded to increase in proportion of UTIs and 
because of limited treatment options for these MDR 
strains; it has become matter of serious concern and 
posing a financial burden too [4]. This study has been 
undertaken to evaluate the susceptibility of uro-
pathogens to newer antimicrobial agents, prulifloxacin, 
fosfomycin (FOM) and doripenem. 
 Prulifloxacin is an oral fluoroquinolone 
specifically a lipophilic prodrug of ulifloxacin. It has 
broad spectrum antimicrobial activity against gram 
positive and gram negative bacteria as well [5]. The in 
vitro activity of prulifloxacin is generally greater than 
that of ciprofloxacin and other flouoroquinolones 
against isolates of Gram-negative bacteria, including 
E. coli, Klebsiella spp., Proteus, Providencia and 
Morganella spp., Pseudomonas aeruginosa, 
Moraxella catarrhalis and Haemophilus spp. Against 
Gram-positive bacteria, such as Streptococcus spp., 
S. aureus, Enterococcus spp. and coagulase-negative 
staphylococci [6], the in vitro activity of ulifloxacin is 
generally similar to or greater than that of 
ciprofloxacin, but lower than that of moxifloxacin [7]. 
FOM has shown promising in vitro activity against 
MDR uropathogens, however sufficient clinical data 
regarding its antimicrobial susceptibility behavior is 
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not available. It is a phosphonic acid derivative and is 
a naturally occurring antibiotic. It acts primarily by 
interfering with bacterial peptidoglycan synthesis and 
hence disrupting cell wall synthesis [8].
 
 It has been 
approved by Food and Drug Administration for the 
treatment of uncomplicated UTIs in women [9]. FOM 
represents its own class of antibiotics and no other 
member of this class is currently approved by 
regulatory agencies worldwide. It has got broad 
spectrum activity against both gram positive and gram 
negative bacteria. It can be administered orally with a 
convenient dosing schedule, including single dose 
therapy for uncomplicated cystitis. Doripenem a 
1beta-methylcarbapenem, is a broad spectrum 
antibiotic which has been approved for intra-
abdominal infections and complicated urinary tract 
infections [10]. The spectrum of activity of doripenem 
has been established in vitro and in vivo for gram 
negative, gram positive and anaerobic micro 
organisms. Compared with the other carbapenems, 
doripenem has a higher threshold for selection of non 
susceptible mutants in vitro, and it seems that high 
level resistance may require the coexistence of more 
than one resistance mechanism [11].
 
 
 
Material and Methods 
 
Samples  
This was a retrospective study with an 
observation period of eighteen months (May 2012 to 
October 2013) during which all the urine samples 
received in the department of Microbiology of Dr. 
Harvansh Sigh Judge Institute of Dental Sciences & 
Hospital were screened for the presence of bacteria. 
In this period of eighteen months the total number of 
samples screened was 259. Qualitative urine cultures 
were performed in CLED agar plates. Plates were 
incubated at 37
0
C for 18-24 h. Identification of the 
bacterial isolates was done using conventional 
biochemical methods [12]. 
 
Antibiotic susceptibility testing 
Besides the antibiotics viz amoxicillin, 
nitrofurantoin, ciprofloxacin, nalidixic acid, augmentin, 
amikacin, ceftazidime, cefotaxime, imepenem and 
sulbactam which are tested in routine; the sensitivity 
pattern of all the E. coli isolates was also tested for 
doripenem, fosfomycin and prulifloxacin. The Clinical 
and Laboratory Standard Institute (CLSI) criterion was 
used for the interpretation of the antimicrobial 
susceptibility [13]. 
 
 
Result and Discussion 
 
Of all the samples received in microbiology 
department during the study period of eighteen 
months 30.8% (80) turned out to be E. coli. The 
susceptibility pattern of the eighty E. coli isolates 
tested for various antibiotics is described in Figure 1. 
 
Antibiogram of E. coli isolates
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Figure 1: Antibogram of E. coli isolates. 
 
Out of eighty E. coli isolates fifteen (18.75%) 
were sensitive to prulifloxacin whereas number of 
isolates that were resistant to prulifloxacin were 65 
(81.75%). If we look at the susceptibility of the E. coli 
isolates towards fluoroquinolones, this study showed 
that the different members of floroquinolones showed 
similar behavior. The finding is supported by another 
study by Carmignani et al. [14]
 
who reported that there 
was no statistical significant difference in the clinical 
and microbiological parameters of prulifloxacin and 
ciprofloxacin.  Other studies [6, 7] have shown that the 
ulifloxacin MICs and minimum bactericidal 
concentrations tend to be equal or even lower 
compared with ciprofloxacin, while they are generally 
lower compared with levofloxacin, for most gram-
negative pathogens including P. aeruginosa. The 
strains of E. coli were altogether sensitive to 
doripenem and fosfomycin as our study reported 
100% susceptibility to both these drugs. Our study 
was supported by another  study by Maraki [15]
  
which 
indicated acivity of fosfomycin against a considerable 
percentage of urinary isolates that simultaneously 
exhibited high rates of antimicrobial drug resistance to 
the conventionally used antimicrobial agents for the 
treatment of UTIs . The excellent activity of fosfomycin 
against E. coli has been reported by similar 
susceptibility findings [16] indicating that the drug is a 
valuable therapeutic option for urinary tract infections. 
In vitro activity of doripenem and other antimicrobial 
agents was evaluated against Gram-negative bacilli 
recently isolated in Brazilian study [17] and these 
studies supported our finding of 100 percent 
susceptibility of uropathogens to doripenem. Hence 
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like other newer drugs, doripenem exhibited excellent 
urinary bactericidal activity and appears to be a good 
alternative in the empirical treatment of UTI and 
pyelonephritis. This study highlighted that 
susceptibility pattern is necessary to obtain sensitivity 
reports before start of antibiotic treatment in cases of 
suspected UTI. The knowledge of antimicrobial 
pattern of routinely isolated uropathogens may 
provide guidance to clinicians regarding the empirical 
treatment of UTI when therapy must be started before 
laboratory reports are available 
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